Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Jan 2025
Biden touts Medicare drug price negotiation and gun safety law, but also warns about AI's dangers
Read Full NewsA secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.
Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.
Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
1.
Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC
2.
Study Linking Fruits, Veggies to Lung Cancer Raises Eyebrows
3.
Climate change is expected to increase the number of suicide deaths
4.
Vaccine shows promise for pancreatic cancer, study finds
5.
Oncology Care Model’s Net Losses Well Exceed Savings
1.
Surgical Innovation Through Bone Marrow–Reserving Surgical Strategies
2.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
3.
Integrated Models in Hematology for Specialists
4.
Emerging Frameworks in Oncology in Clinical Decision-Making
5.
Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
Should We Use DARA Up Front As First-Line Therapy in MM?
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
5.
How Platelet Disorders Can Affect the Body
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge